Table 4. Baseline characteristics for the LEUVEN group according to rs1051730 and rs8034191 genotypes.
| rs1051730 | rs81034191 | |||||||
| AA | AG | GG | P-value | GG | AG | AA | P-value | |
| Demographics | ||||||||
| Age | 63.9 (7.8) | 63.4 (8.0) | 64.7 (8.0) | 0.086 | 63.5 (7.9) | 63.6 (8.0) | 64.6 (8.0) | 0.234 |
| Pack-years history, mean (SD), yr | 45.5 (21.6) | 49.6 (26.7) | 45.9 (23.9) | 0.080 | 46.2 (22.2) | 49.4 (26.6) | 45.7 (23.5) | 0.103 |
| Current smokers, no (%) | 44 (38.3) | 170 (47.2) | 147 (48.8) | 0.144 | 52 (41.3) | 167 (45.5) | 146 (50.2) | 0.211 |
| Pulmonary function tests, mean (SD) | ||||||||
| FEV1, L, post | 1.74 (1.04) | 1.93 (1.09) | 1.98 (1.07) | 0.088 | 1.77 (1.06) | 1.93 (1.08) | 1.98 (1.08) | 0.146 |
| FEV1, % predicted, post | 59.8 (31.6) | 65.5 (32.6) | 68.1 (33.1) | 0.044 | 60.7 (32.6) | 65.6 (32.0) | 67.5 (33.4) | 0.111 |
| FEV1/FVC ratio, | 0.51 (0.18) | 0.54 (0.18) | 0.55 (0.18) | 0.054 | 0.51 (0.18) | 0.54 (0.18) | 0.55 (0.18) | 0.045 |
| COPD severity, no. (%) | 0.444 | 0.385 | ||||||
| No bronchial obstruction | 30 (13.1) | 106 (46.3) | 93 (40.6) | 31 (13.5) | 109 (47.4) | 90 (39.1) | ||
| GOLD class I | 18 (14.8) | 51 (41.8) | 53 (43.4) | 22 (17.9) | 52 (42.3) | 49 (39.8) | ||
| GOLD class II | 27 (15.0) | 89 (49.4) | 64 (35.6) | 28 (15.3) | 93 (50.8) | 62 (33.9) | ||
| GOLD class III | 27 (14.4) | 85 (45.5) | 75 (40.1) | 29 (15.4) | 86 (45.7) | 73 (38.8) | ||
| GOLD class IV | 33 (21.2) | 71 (45.5) | 52 (33.3) | 36 (22.6) | 69 (43.4) | 54 (34.0) | ||
| Clinical Category, no. (%) | 0.018 | 0.067 | ||||||
| Asymptomatic smokers | 43 (11.8) | 175 (48.2) | 145 (39.9) | 48 (13.1) | 176 (48.1) | 142 (38.8) | ||
| Ambulatory COPD patients | 62 (15.9) | 176 (45.1) | 152 (39.0) | 68 (17.3) | 182 (46.2) | 144 (36.5) | ||
| Patients with end-stage COPD | 30 (24.8) | 51 (42.1) | 40 (33.1) | 30 (24.4) | 51 (41.5) | 42 (34.1) | ||
Genotyping succeeded in 874 (99%) and 883 (100%) LEUVEN participants, respectively for rs1051730 and rs8034191.